# Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

> **NCT02682407** · PHASE2 · TERMINATED · sponsor: **Omeros Corporation** · enrollment: 31 (actual)

## Conditions studied

- IgAN
- LN
- MN
- C3G

## Interventions

- **BIOLOGICAL:** OMS721 (narsoplimab)

## Key facts

- **NCT ID:** NCT02682407
- **Lead sponsor:** Omeros Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03-10
- **Primary completion:** 2020-08-25
- **Final completion:** 2020-08-25
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Study terminated by Sponsor
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02682407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02682407, "Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02682407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*